Benzinga | Aug 10, 2020 07:43AM EDT

Intra-Cellular Therapies Q2 EPS $(0.96) Misses $(0.91) Estimate, Sales $1.91M Miss $3.03M Estimate

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.91) by 5.49 percent. This is a 41.18 percent decrease over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $1.91 million which missed the analyst consensus estimate of $3.03 million by 37.06 percent.